SanegeneBio Announces RNAi Global Licensing Collaboration with Genentech
-SanegeneBio grants exclusive worldwide license to one of its RNAi programs to Genentech- -SanegeneBio to receive $200 million upfront payment and will be eligible to receive development and commercialization milestone payments, totaling up to $1.5 billion, plus tiered royalties- -Genentech will be responsible for the subsequent clinical development and commercialization globally- BOSTON, SHANGHAI, and SUZHOU […]
SanegeneBio Announces First Patient Dosed in Phase 1 Trial of SGB-7342
BOSTON, SHANGHAI, and SUZHOU – January 13, 2026, SanegeneBio, a clinical-stage biotechnology company developing innovative RNAi therapeutics, announced that the first patient has recently been dosed in a Phase 1 clinical trial of SGB-7342 at the first hospital of Jilin University in China. This randomized, double-blind, placebo controlled, single ascending dose Phase 1 clinical trial […]
SanegeneBio Receives NMPA Approval to Initiate Clinical Trials of SGB-7342 for Obesity
-The Phase I clinical trial for SGB-7342 is scheduled to initiate in early 2026- BOSTON, SHANGHAI, and SUZHOU – December 16, 2025, SanegeneBio, a clinical-stage biotechnology company developing innovative RNAi therapeutics, today announced that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has approved its Investigational New Drug (IND) application […]
SanegeneBio Raises over $110 Million in Series B Financing
BOSTON, SHANGHAI, and SUZHOU — December 8, 2025, SanegeneBio, a clinical-stage biotechnology company developing innovative RNAi therapeutics, announced the closing of Series B financing round, raising over $110 million. The financing will advance its clinical stage assets towards registrational studies and accelerate the development of programs across several therapeutic areas, powered by its industry-leading RNAi […]
SanegeneBio Announces Phase 1 Clinical Data for SGB-9768 Presented at ASN Kidney Week 2025
-SGB-9768 demonstrates a favorable safety and tolerability profile in healthy volunteers (HVs), achieving significant, dose-dependent, and sustained reduction in serum C3 and inhibition of alternative pathway (AP) activity after single-dose subcutaneous (SC) administration- -The results support its further investigation for the treatment of complement-mediated kidney diseases such as IgA Nephropathy (IgAN) and C3 Glomerulopathy (C3G)- […]
SanegeneBio and Innovent Announce Phase 1 Clinical Data for SGB-3908 Presented at American Heart Association (AHA) 2025 Annual Meeting
-SGB-3908 demonstrates sustained and potent AGT mRNA suppression with preliminary evidence of antihypertensive efficacy after single-dose subcutaneous administration- -The clinical Phase 1 data of SGB-3908 further support the potential for biannual subcutaneous dosing for the treatment of hypertension. Next-step development is scheduled to initiate soon- BOSTON, SHANGHAI, and SUZHOU – November 10, 2025, SanegeneBio, a […]
SanegeneBio Announces RNAi Licensing and Research Collaboration with Lilly
-Companies will collaborate on RNAi research for metabolic disease targets- BOSTON, SHANGHAI, and SUZHOU – November 8, 2025, SanegeneBio, a clinical-stage biotechnology company developing innovative RNAi therapeutics, today announced a global research and licensing collaboration with Eli Lilly and Company (“Lilly”). The companies will collaborate to advance RNAi candidates for metabolic diseases, based on SanegeneBio’s […]
SGB-9768 Clinical Data to be Reported at ASN Kidney Week 2025
BOSTON, SHANGHAI, and SUZHOU – October 25, 2025, SanegeneBio, a clinical-stage biotechnology focused on developing best-in-class RNAi medicines for obesity, cardiometabolic, and autoimmune diseases, today announced its participation at the American Society of Nephrology (ASN) Kidney Week 2025, November 5-9 in Houston, TX, USA. Safety and pharmacodynamic data from two Phase I studies of SGB-9768, […]
SanegeneBio Announces FDA Orphan Drug Designation for SGB-9768, an Experimental RNAi Medicine Targeting C3 mRNA
-FDA Grants Orphan Drug Designation to SGB-9768 for C3 Glomerulopathy, a rare and devastating kidney disease- -SGB-9768 has the potential to transform the treatment landscape of C3G and offer a new option to patients- BOSTON, SHANGHAI, and SUZHOU – October 21, 2025, SanegeneBio, a clinical-stage RNAi therapeutics company, today announced that the U.S. Food and […]
SanegeneBio Receives NMPA Approval to Initiate Clinical Trial of SGB-3383 for Complement-Mediated Blood Disorders
— A new approval to study evaluates efficacy and safety in complement-mediated blood disorders: Paroxysmal Nocturnal Hemoglobinuria (PNH) and Atypical Hemolytic Uremic Syndrome (aHUS) — BOSTON, SHANGHAI, and SUZHOU – September 19, 2025, SanegeneBio, a clinical-stage RNAi therapeutics company, today announced that China’s National Medical Products Administration (NMPA) has approved SGB-3383 to initiate a clinical […]